FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378953758> ?p ?o ?g. }

• W4378953758 abstract "It has been reported that people with COVID-19 and pre-existing autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm responsible for severe respiratory symptoms. Since interleukin 6 (IL-6) is one of the cytokines released during this inflammatory process, IL-6 blocking agents have been used for treating people with severe COVID-19.To update the evidence on the effectiveness and safety of IL-6 blocking agents compared to standard care alone or to a placebo for people with COVID-19.We searched the World Health Organization (WHO) International Clinical Trials Registry Platform, the Living OVerview of Evidence (L·OVE) platform, and the Cochrane COVID-19 Study Register to identify studies on 7 June 2022.We included randomized controlled trials (RCTs) evaluating IL-6 blocking agents compared to standard care alone or to placebo for people with COVID-19, regardless of disease severity.Pairs of researchers independently conducted study selection, extracted data and assessed risk of bias. We assessed the certainty of evidence using the GRADE approach for all critical and important outcomes. In this update we amended our protocol to update the methods used for grading evidence by establishing minimal important differences for the critical outcomes.This update includes 22 additional trials, for a total of 32 trials including 12,160 randomized participants all hospitalized for COVID-19 disease. We identified a further 17 registered RCTs evaluating IL-6 blocking agents without results available as of 7 June 2022. The mean age range varied from 56 to 75 years; 66.2% (8051/12,160) of enrolled participants were men. One-third (11/32) of included trials were placebo-controlled. Twenty-two were published in peer-reviewed journals, three were reported as preprints, two trials had results posted only on registries, and results from five trials were retrieved from another meta-analysis. Eight were funded by pharmaceutical companies. Twenty-six included studies were multicenter trials; four were multinational and 22 took place in single countries. Recruitment of participants occurred between February 2020 and June 2021, with a mean enrollment duration of 21 weeks (range 1 to 54 weeks). Nineteen trials (60%) had a follow-up of 60 days or more. Disease severity ranged from mild to critical disease. The proportion of participants who were intubated at study inclusion also varied from 5% to 95%. Only six trials reported vaccination status; there were no vaccinated participants included in these trials, and 17 trials were conducted before vaccination was rolled out. We assessed a total of six treatments, each compared to placebo or standard care. Twenty trials assessed tocilizumab, nine assessed sarilumab, and two assessed clazakizumab. Only one trial was included for each of the other IL-6 blocking agents (siltuximab, olokizumab, and levilimab). Two trials assessed more than one treatment. Efficacy and safety of tocilizumab and sarilumab compared to standard care or placebo for treating COVID-19 At day (D) 28, tocilizumab and sarilumab probably result in little or no increase in clinical improvement (tocilizumab: risk ratio (RR) 1.05, 95% confidence interval (CI) 1.00 to 1.11; 15 RCTs, 6116 participants; moderate-certainty evidence; sarilumab: RR 0.99, 95% CI 0.94 to 1.05; 7 RCTs, 2425 participants; moderate-certainty evidence). For clinical improvement at ≥ D60, the certainty of evidence is very low for both tocilizumab (RR 1.10, 95% CI 0.81 to 1.48; 1 RCT, 97 participants; very low-certainty evidence) and sarilumab (RR 1.22, 95% CI 0.91 to 1.63; 2 RCTs, 239 participants; very low-certainty evidence). The effect of tocilizumab on the proportion of participants with a WHO Clinical Progression Score (WHO-CPS) of level 7 or above remains uncertain at D28 (RR 0.90, 95% CI 0.72 to 1.12; 13 RCTs, 2117 participants; low-certainty evidence) and that for sarilumab very uncertain (RR 1.10, 95% CI 0.90 to 1.33; 5 RCTs, 886 participants; very low-certainty evidence). Tocilizumab reduces all cause-mortality at D28 compared to standard care/placebo (RR 0.88, 95% CI 0.81 to 0.94; 18 RCTs, 7428 participants; high-certainty evidence). The evidence about the effect of sarilumab on this outcome is very uncertain (RR 1.06, 95% CI 0.86 to 1.30; 9 RCTs, 3305 participants; very low-certainty evidence). The evidence is uncertain for all cause-mortality at ≥ D60 for tocilizumab (RR 0.91, 95% CI 0.80 to 1.04; 9 RCTs, 2775 participants; low-certainty evidence) and very uncertain for sarilumab (RR 0.95, 95% CI 0.84 to 1.07; 6 RCTs, 3379 participants; very low-certainty evidence). Tocilizumab probably results in little to no difference in the risk of adverse events (RR 1.03, 95% CI 0.95 to 1.12; 9 RCTs, 1811 participants; moderate-certainty evidence). The evidence about adverse events for sarilumab is uncertain (RR 1.12, 95% CI 0.97 to 1.28; 4 RCT, 860 participants; low-certainty evidence). The evidence about serious adverse events is very uncertain for tocilizumab (RR 0.93, 95% CI 0.81 to 1.07; 16 RCTs; 2974 participants; very low-certainty evidence) and uncertain for sarilumab (RR 1.09, 95% CI 0.97 to 1.21; 6 RCTs; 2936 participants; low-certainty evidence). Efficacy and safety of clazakizumab, olokizumab, siltuximab and levilimab compared to standard care or placebo for treating COVID-19 The evidence about the effects of clazakizumab, olokizumab, siltuximab, and levilimab comes from only one or two studies for each blocking agent, and is uncertain or very uncertain.In hospitalized people with COVID-19, results show a beneficial effect of tocilizumab on all-cause mortality in the short term and probably little or no difference in the risk of adverse events compared to standard care alone or placebo. Nevertheless, both tocilizumab and sarilumab probably result in little or no increase in clinical improvement at D28. Evidence for an effect of sarilumab and the other IL-6 blocking agents on critical outcomes is uncertain or very uncertain. Most of the trials included in our review were done before the waves of different variants of concern and before vaccination was rolled out on a large scale. An additional 17 RCTs of IL-6 blocking agents are currently registered with no results yet reported. The number of pending studies and the number of participants planned is low. Consequently, we will not publish further updates of this review." @default.
• W4378953758 created "2023-06-02" @default.
• W4378953758 creator A5000280447 @default.
• W4378953758 creator A5010569274 @default.
• W4378953758 creator A5011712149 @default.
• W4378953758 creator A5017009529 @default.
• W4378953758 creator A5027839435 @default.
• W4378953758 creator A5029170866 @default.
• W4378953758 creator A5033321113 @default.
• W4378953758 creator A5036345545 @default.
• W4378953758 creator A5038009611 @default.
• W4378953758 creator A5038731071 @default.
• W4378953758 creator A5040036979 @default.
• W4378953758 creator A5040110773 @default.
• W4378953758 creator A5042080706 @default.
• W4378953758 creator A5045420411 @default.
• W4378953758 creator A5052581893 @default.
• W4378953758 creator A5053358581 @default.
• W4378953758 creator A5056473120 @default.
• W4378953758 creator A5057755516 @default.
• W4378953758 creator A5058645290 @default.
• W4378953758 creator A5065028933 @default.
• W4378953758 creator A5066761906 @default.
• W4378953758 creator A5066861352 @default.
• W4378953758 creator A5068078908 @default.
• W4378953758 creator A5070817601 @default.
• W4378953758 creator A5075828719 @default.
• W4378953758 creator A5078390860 @default.
• W4378953758 creator A5086703166 @default.
• W4378953758 creator A5088280831 @default.
• W4378953758 creator A5090381428 @default.
• W4378953758 date "2023-06-01" @default.
• W4378953758 modified "2023-10-17" @default.
• W4378953758 title "Interleukin-6 blocking agents for treating COVID-19: a living systematic review" @default.
• W4378953758 cites W1973914781 @default.
• W4378953758 cites W2084217732 @default.
• W4378953758 cites W2088095316 @default.
• W4378953758 cites W2139168999 @default.
• W4378953758 cites W2144034723 @default.
• W4378953758 cites W2144233368 @default.
• W4378953758 cites W2560438049 @default.
• W4378953758 cites W2737436316 @default.
• W4378953758 cites W2765166506 @default.
• W4378953758 cites W2893332348 @default.
• W4378953758 cites W2900818704 @default.
• W4378953758 cites W2970684805 @default.
• W4378953758 cites W2975424845 @default.
• W4378953758 cites W3012421327 @default.
• W4378953758 cites W3014001472 @default.
• W4378953758 cites W3014527183 @default.
• W4378953758 cites W3025160648 @default.
• W4378953758 cites W3030158388 @default.
• W4378953758 cites W3034858522 @default.
• W4378953758 cites W3036398841 @default.
• W4378953758 cites W3042099270 @default.
• W4378953758 cites W3043831218 @default.
• W4378953758 cites W3044304208 @default.
• W4378953758 cites W3045190421 @default.
• W4378953758 cites W3046396978 @default.
• W4378953758 cites W3048885045 @default.
• W4378953758 cites W3081275185 @default.
• W4378953758 cites W3082153866 @default.
• W4378953758 cites W3082432046 @default.
• W4378953758 cites W3083818259 @default.
• W4378953758 cites W3084707698 @default.
• W4378953758 cites W3088161102 @default.
• W4378953758 cites W3088256443 @default.
• W4378953758 cites W3088609942 @default.
• W4378953758 cites W3091085673 @default.
• W4378953758 cites W3091337946 @default.
• W4378953758 cites W3092887721 @default.
• W4378953758 cites W3093035082 @default.
• W4378953758 cites W3093604087 @default.
• W4378953758 cites W3093837118 @default.
• W4378953758 cites W3094609299 @default.
• W4378953758 cites W3096119943 @default.
• W4378953758 cites W3097110943 @default.
• W4378953758 cites W3097807388 @default.
• W4378953758 cites W3107596380 @default.
• W4378953758 cites W3110844195 @default.
• W4378953758 cites W3111106539 @default.
• W4378953758 cites W3111262560 @default.
• W4378953758 cites W3113196149 @default.
• W4378953758 cites W3121693389 @default.
• W4378953758 cites W3124292577 @default.
• W4378953758 cites W3126231175 @default.
• W4378953758 cites W3127659442 @default.
• W4378953758 cites W3129869280 @default.
• W4378953758 cites W3130126061 @default.
• W4378953758 cites W3134062749 @default.
• W4378953758 cites W3134173365 @default.
• W4378953758 cites W3134383271 @default.
• W4378953758 cites W3134507486 @default.
• W4378953758 cites W3134674969 @default.
• W4378953758 cites W3135652442 @default.
• W4378953758 cites W3135838854 @default.
• W4378953758 cites W3137250952 @default.
• W4378953758 cites W3141007276 @default.
• W4378953758 cites W3153080479 @default.
• W4378953758 cites W3157210032 @default.

• next